Lymphocyte subsets fluctuate even in healthy people with no underlying disease, and small changes in the overall pool of lymphocytes bearing certain phenotypic markers such as CD4 or CD8 are ...

Lymphoproliferative syndrome with well differentiated lymphocytes and moderate lymphocytosis in the peripheral blood includes a heterogeneous group of disorders, that present often difficulties in ...

Source: Terradas R, Grau S, Blanch J, Riu M, Saballs P, et al. (2012) Eosinophil Count and Neutrophil-Lymphocyte Count Ratio as Prognostic Markers in Patients with Bacteremia: A Retrospective Cohort ...

Preoperative monocyte lymphocyte ratio (MLR) is an effective blood marker to predict heightened three-year mortality in older adults who have experienced hip fracture and had surgery for it, a new ...

Patients with colorectal cancer (CRC) can use C-reactive protein (CRP), lymphocyte to CRP ratio, and CRP to albumin ratio as markers for CRC prognosis.

The platelet-to-lymphocyte ratio has potential to be a marker of mortality for patients with AKI, according to data published in Kidney Medicine.“ [Platelet-to-lymphocyte ratio] PLR has been ...

Lymphocyte-depleted Hodgkin's lymphoma (LDHL) is a type of Hodgkin’s lymphoma, a cancer that develops in the lymphatic system. Symptoms include painless swelling of the lymph nodes, shortness of ...

Patients with a neutrophil-to-lymphocyte ratio (NLR) above 4.8 had significantly worse clinical outcomes. Elevated NLR was ...

Serum markers like beta-2 microglobulin and thymidine kinase also correlate with disease progression and treatment response, with serum TK values above 48.5 U/L having a more rapid lymphocyte ...

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.. If you have ...

Derived neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio as a prognostic marker for patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.